Schilling WHK, Mukaka M, Callery JJ, Llewelyn MJ, Cruz CV, et al.
2024-09-12 • PLOS Medicine
2024-09-12 • PLOS Medicine
BACKGROUND
Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety an...
Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, et al.
2008-01-01 • Tropical Medicine and International Health
2008-01-01 • Tropical Medicine and International Health
OBJECTIVE: To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria in in Dawei District, southern Myanmar. METHODS: Enrolled patients at Sonsinphya clinic >6 m...
Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JH, et al.
2007-04-01 • Journal of Infectious Diseases
2007-04-01 • Journal of Infectious Diseases
BACKGROUND: Relapses originating from hypnozoites are characteristic of Plasmodium vivax infections. Thus, reappearance of parasitemia after treatment can result from relapse, recrudesce...
Falq G, Van der Bergh R, de Smet M, Etienne W, Nguon C, et al.
2016-09-01 • Malaria Journal
2016-09-01 • Malaria Journal
BACKGROUND In Cambodia, elimination of artemisinin resistance through direct elimination of the Plasmodium falciparum parasite may be the only strategy. Prevalence and incidence at d...
Smithuis FM, Kyaw MK, Phe O, Win T, Aung PP, et al.
2010-10-01 • Lancet Infectious Diseases
2010-10-01 • Lancet Infectious Diseases
BACKGROUND: Artemisinin-combination therapy (ACT) is recommended as first-line treatment of falciparum malaria throughout the world, and fixed-dose combinations are preferred by WHO; whe...
Grist EP, Fleqq JA, Humphreys G, Mas IS, Anderson TJC, et al.
2016-10-24 • International Journal of Health Geographics
2016-10-24 • International Journal of Health Geographics
BACKGROUND Artemisinin-resistant Plasmodium falciparum malaria parasites are now present across much of mainland Southeast Asia, where ongoing surveys are measuring and mapping their...